Source: Highmark Marketing Press Release 11-5-14
VANCOUVER, BRITISH COLUMBIA–(Marketwired – Nov. 5, 2014) – Highmark Marketing Inc. (CSE:HMK)(FRANKFURT:1HM)(PINKSHEETS:HMKTF) (“Highmark“) is pleased to announce that MJ Bioscience, has received a high efficiency platform design (the “Platform Design“) for large scale clonal micropropagation of cannabis plants from Dr. Yevtushenko, PhD. MJ Bioscience is a wholly-owned subsidiary of Highmark conducting R&D on cannabis propagation strategies, strains and extraction methods.
The Platform Design has been developed for the exclusive use of MJ Bioscience. The Platform Design includes two main processes, tissue culture, and bioreactors, which may be used together or as independent stand-alone processes. MJ Bioscience intends to use the two components together.
The Platform Design and its processes include components such as the development of efficient media (soil) composition, the establishment of culture conditions applicable to high efficiency cannabis propagation, and the use of temporary immersion bioreactors (TIBs).
Specifically, bioreactor systems offer several compelling advantages over traditional tissue culture techniques:
- The production of more plants per square foot;
- Enhanced growth and higher multiplication rates;
- Shortened time for plant multiplication and the growth cycle;
- Improved plant quality;
- Lower costs for liquid media vs. gel-solidified;
- Reduced labour inputs;
- Improved nutrient uptake;
- A platform which is relatively easy to scale-up;
- Automated, large-scale plant propagation.
The Platform Design includes a number of features that are proprietary in nature, and include but are not limited to the following:
I. Media Composition
- type, form, composition of macro- and micronutrients
- concentration of vitamins
- source of carbohydrates
- type, concentration, ratio of plant growth regulators
II. Environmental Parameters
- tissue culture techniques
- light intensity
- duration of photoperiod
III. Bioreactor design
The next step shall be confirmation studies to validate the design concept. The final platform is expected to be a novel patentable process to create high quality disease-free cannabis plants on a very large scale at low cost. In addition to utilizing this strategy as one of MJ Bioscience’s business lines. The micropropagation strategy will be used to support the low-cost and efficient creation of proprietary strains and compounds, and to test derivatives and extractions.
The demand for low-cost cannabis plants is expected to undergo a period of fast growth over the coming years as the producers of legal medical and recreational marijuana in markets around the world ramp up their supply to meet increasing demand. MJ Bioscience’s cannabis propagation strategies, by adopting technologies which have until now not been broadly deployed in the marijuana growing markets, expects to be positioned at the forefront of propagation strategies for cannabis.
Dr. Yevtushenko is now working on the development of an innovative breeding platform for the production of new plant varieties with higher cannabinoids yield and desired trait combinations.
The MJ Bioscience website is located at www.mjbioscience.com.
Highmark, based in British Columbia, is a nutraceutical company, with a specific focus on the medical marijuana industry. Highmark has three primary divisions: a growing division, the MJ Bioscience R&D division and the Mobiweed technology division. Through these three divisions, Highmark intends to provide its shareholders with exposure to many opportunities in the growing medical marijuana markets.
Further information about Highmark is available under its profile on the SEDAR website www.sedar.com and on Highmark’s page on the CSE website.
The CSE has not reviewed, nor approved or disapproved the content of this press release.
This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of Highmark. Forward-looking information is based on certain key expectations and assumptions made by the management of Highmark, including future plans for acquisitions. Although Highmark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because Highmark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. Highmark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
Highmark Marketing Inc.
Chief Executive Officer